AG˹ٷ

STOCK TITAN

[8-K] Voyager Therapeutics, Inc. Reports Material Event

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
8-K
Rhea-AI Filing Summary

MarineMax (HZO) Form 8-K � Board changes

On 04-Aug-2025 directors Clint Moore and Evelyn Follit resigned; the company states the departures were not due to any disagreement regarding operations, policies or practices.

Effective the same day, the Board appointed Odilon Almeida Jr. as an independent Class I director and member of the Audit Committee, with a term expiring at the 2026 annual meeting. His compensation will mirror that of other independent directors and no related-party transactions were reported.

Following the resignations and appointment, MarineMax’s Board remains composed of eight directors. A press release announcing the changes was issued 05-Aug-2025 and is furnished as Exhibit 99.1.

MarineMax (HZO) Modulo 8-K � Cambiamenti nel Consiglio

Il 04 agosto 2025 i direttori Clint Moore ed Evelyn Follit si sono dimessi; la società dichiara che le dimissioni non sono state dovute a disaccordi riguardanti operazioni, politiche o pratiche.

Con effetto nello stesso giorno, il Consiglio ha nominato Odilon Almeida Jr. come direttore indipendente di Classe I e membro del Comitato di Revisione, con un mandato che scade all'assemblea annuale del 2026. La sua remunerazione sarà equivalente a quella degli altri direttori indipendenti e non sono state segnalate operazioni con parti correlate.

Dopo le dimissioni e la nomina, il Consiglio di MarineMax rimane composto da otto direttori. Un comunicato stampa che annuncia i cambiamenti è stato pubblicato il 05 agosto 2025 ed è fornito come Allegato 99.1.

MarineMax (HZO) Formulario 8-K � Cambios en la Junta

El 04 de agosto de 2025, los directores Clint Moore y Evelyn Follit renunciaron; la empresa afirma que las salidas no se debieron a ningún desacuerdo relacionado con operaciones, políticas o prácticas.

Con efecto el mismo día, la Junta nombró a Odilon Almeida Jr. como director independiente de Clase I y miembro del Comité de Auditoría, con un mandato que expira en la reunión anual de 2026. Su compensación será igual a la de otros directores independientes y no se reportaron transacciones con partes relacionadas.

Tras las renuncias y el nombramiento, la Junta de MarineMax sigue compuesta por ocho directores. Un comunicado de prensa anunciando los cambios fue emitido el 05 de agosto de 2025 y se presenta como Anexo 99.1.

MarineMax (HZO) Form 8-K � 이사� 변� 사항

2025� 8� 4�, 이사 Clint Moore와 Evelyn Follit가 사임하였으며, 회사� 이들� 사임� 운영, 정책 또는 관행과 관련된 어떠� 불일� 때문� 아님� 명시하였습니�.

동일� 날부�, 이사회는 Odilon Almeida Jr.� 독립적인 클래� I 이사이자 감사위원� 위원으로 임명하였으며, 임기� 2026� 연례 총회까지입니�. 그의 보수� 다른 독립 이사들과 동일하며, 관� 당사� 거래� 보고되지 않았습니�.

사임� 임명 이후에도 MarineMax 이사회는 여전� 8명의 이사� 구성되어 있습니다. 변� 사항� 알리� 보도자료� 2025� 8� 5일에 발표되었으며, 부속서 99.1� 제공됩니�.

MarineMax (HZO) Formulaire 8-K � Changements au sein du conseil d'administration

Le 4 août 2025, les administrateurs Clint Moore et Evelyn Follit ont démissionné ; la société précise que ces départs ne résultent d’aucun désaccord concernant les opérations, les politiques ou les pratiques.

À compter de ce même jour, le conseil a nommé Odilon Almeida Jr. en tant qu’administrateur indépendant de classe I et membre du comité d’audit, avec un mandat expirant lors de l’assemblée générale annuelle de 2026. Sa rémunération sera alignée sur celle des autres administrateurs indépendants et aucune transaction avec des parties liées n’a été signalée.

Suite aux démissions et à la nomination, le conseil d’administration de MarineMax reste composé de huit membres. Un communiqué de presse annonçant ces changements a été publié le 5 août 2025 et est fourni en tant qu’Annexe 99.1.

MarineMax (HZO) Form 8-K � Änderungen im Vorstand

Am 04. August 2025 traten die Direktoren Clint Moore und Evelyn Follit zurück; das Unternehmen erklärt, dass die Abgänge nicht auf Meinungsverschiedenheiten bezüglich der Geschäftstätigkeiten, Richtlinien oder Praktiken zurückzuführen sind.

Mit Wirkung zum selben Tag ernannte der Vorstand Odilon Almeida Jr. zum unabhängigen Direktor der Klasse I und Mitglied des Prüfungsausschusses, mit einer Amtszeit bis zur Jahreshauptversammlung 2026. Seine Vergütung entspricht der der anderen unabhängigen Direktoren, und es wurden keine Transaktionen mit verbundenen Parteien gemeldet.

Nach den Rücktritten und der Ernennung besteht der Vorstand von MarineMax weiterhin aus acht Direktoren. Eine Pressemitteilung zur Ankündigung der Änderungen wurde am 05. August 2025 veröffentlicht und als Anlage 99.1 bereitgestellt.

Positive
  • None.
Negative
  • None.

Insights

TL;DR: Routine board refresh; neutral financial impact; governance continuity intact.

The simultaneous resignation of two directors and appointment of a single independent replacement keeps the Board at eight members and preserves Audit Committee independence, suggesting no governance gap. Because the company affirms there were no disagreements and the new director has no related-party ties, investor risk exposure appears unchanged. Absent operational or financial ramifications, the filing should be viewed as administratively neutral.

MarineMax (HZO) Modulo 8-K � Cambiamenti nel Consiglio

Il 04 agosto 2025 i direttori Clint Moore ed Evelyn Follit si sono dimessi; la società dichiara che le dimissioni non sono state dovute a disaccordi riguardanti operazioni, politiche o pratiche.

Con effetto nello stesso giorno, il Consiglio ha nominato Odilon Almeida Jr. come direttore indipendente di Classe I e membro del Comitato di Revisione, con un mandato che scade all'assemblea annuale del 2026. La sua remunerazione sarà equivalente a quella degli altri direttori indipendenti e non sono state segnalate operazioni con parti correlate.

Dopo le dimissioni e la nomina, il Consiglio di MarineMax rimane composto da otto direttori. Un comunicato stampa che annuncia i cambiamenti è stato pubblicato il 05 agosto 2025 ed è fornito come Allegato 99.1.

MarineMax (HZO) Formulario 8-K � Cambios en la Junta

El 04 de agosto de 2025, los directores Clint Moore y Evelyn Follit renunciaron; la empresa afirma que las salidas no se debieron a ningún desacuerdo relacionado con operaciones, políticas o prácticas.

Con efecto el mismo día, la Junta nombró a Odilon Almeida Jr. como director independiente de Clase I y miembro del Comité de Auditoría, con un mandato que expira en la reunión anual de 2026. Su compensación será igual a la de otros directores independientes y no se reportaron transacciones con partes relacionadas.

Tras las renuncias y el nombramiento, la Junta de MarineMax sigue compuesta por ocho directores. Un comunicado de prensa anunciando los cambios fue emitido el 05 de agosto de 2025 y se presenta como Anexo 99.1.

MarineMax (HZO) Form 8-K � 이사� 변� 사항

2025� 8� 4�, 이사 Clint Moore와 Evelyn Follit가 사임하였으며, 회사� 이들� 사임� 운영, 정책 또는 관행과 관련된 어떠� 불일� 때문� 아님� 명시하였습니�.

동일� 날부�, 이사회는 Odilon Almeida Jr.� 독립적인 클래� I 이사이자 감사위원� 위원으로 임명하였으며, 임기� 2026� 연례 총회까지입니�. 그의 보수� 다른 독립 이사들과 동일하며, 관� 당사� 거래� 보고되지 않았습니�.

사임� 임명 이후에도 MarineMax 이사회는 여전� 8명의 이사� 구성되어 있습니다. 변� 사항� 알리� 보도자료� 2025� 8� 5일에 발표되었으며, 부속서 99.1� 제공됩니�.

MarineMax (HZO) Formulaire 8-K � Changements au sein du conseil d'administration

Le 4 août 2025, les administrateurs Clint Moore et Evelyn Follit ont démissionné ; la société précise que ces départs ne résultent d’aucun désaccord concernant les opérations, les politiques ou les pratiques.

À compter de ce même jour, le conseil a nommé Odilon Almeida Jr. en tant qu’administrateur indépendant de classe I et membre du comité d’audit, avec un mandat expirant lors de l’assemblée générale annuelle de 2026. Sa rémunération sera alignée sur celle des autres administrateurs indépendants et aucune transaction avec des parties liées n’a été signalée.

Suite aux démissions et à la nomination, le conseil d’administration de MarineMax reste composé de huit membres. Un communiqué de presse annonçant ces changements a été publié le 5 août 2025 et est fourni en tant qu’Annexe 99.1.

MarineMax (HZO) Form 8-K � Änderungen im Vorstand

Am 04. August 2025 traten die Direktoren Clint Moore und Evelyn Follit zurück; das Unternehmen erklärt, dass die Abgänge nicht auf Meinungsverschiedenheiten bezüglich der Geschäftstätigkeiten, Richtlinien oder Praktiken zurückzuführen sind.

Mit Wirkung zum selben Tag ernannte der Vorstand Odilon Almeida Jr. zum unabhängigen Direktor der Klasse I und Mitglied des Prüfungsausschusses, mit einer Amtszeit bis zur Jahreshauptversammlung 2026. Seine Vergütung entspricht der der anderen unabhängigen Direktoren, und es wurden keine Transaktionen mit verbundenen Parteien gemeldet.

Nach den Rücktritten und der Ernennung besteht der Vorstand von MarineMax weiterhin aus acht Direktoren. Eine Pressemitteilung zur Ankündigung der Änderungen wurde am 05. August 2025 veröffentlicht und als Anlage 99.1 bereitgestellt.

0001640266false00016402662025-08-062025-08-06

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of The Securities Exchange Act of 1934

Date of Report (Date of Earliest Event Reported): August 6, 2025

Voyager Therapeutics, Inc.

(Exact name of registrant as specified in its charter)

Delaware

001-37625

46-3003182

(State or other jurisdiction
of incorporation)

(Commission
File Number)

(I.R.S. Employer
Identification No.)

75 Hayden Avenue
Lexington, Massachusetts

02421

(Address of principal executive offices)

(Zip Code)

Registrant’s telephone number, including area code (857) 259-5340

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

Trading Symbol(s)

Name of each exchange on which registered

Common Stock, $0.001 par value

VYGR

Nasdaq Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

Item 2.02. Results of Operations and Financial Condition.

On August 6 2025, Voyager Therapeutics, Inc. (the “Company”) announced second quarter 2025 financial results and corporate updates. The full text of the press release issued in connection with the announcement is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated by reference herein.

The information in Item 2.02 of this Current Report on Form 8-K (including Exhibit 99.1) shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.

Item 9.01. Financial Statements and Exhibits

(d)    Exhibits

The following exhibit relating to Item 2.02 shall be deemed to be furnished, and not filed:

Exhibit
No.

Description

99.1

Press release dated August 6, 2025 entitled “Voyager Reports Second Quarter 2025 Financial and Operating Results”.

104

Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101).

2

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

ar

Date: August 6, 2025

VOYAGER THERAPEUTICS, INC.

By:

/s/ Alfred Sandrock, M.D., Ph.D.

Alfred Sandrock, M.D., Ph.D.

Chief Executive Officer, President, and Director

(Principal Executive Officer)

3

FAQ

Why did Clint Moore and Evelyn Follit resign from MarineMax's (HZO) board?

Both directors resigned effective 04-Aug-2025, and the 8-K states their departures were not due to any disagreements with the company.

Who was appointed to MarineMax's board on 04-Aug-2025 and what committee will he join?

The Board appointed Odilon Almeida Jr. as an independent director and member of the Audit Committee.

How many directors does MarineMax have after the changes?

Following the resignations and appointment, the Board will consist of eight directors.

Is the newly appointed director considered independent?

Yes. The Board determined that Odilon Almeida Jr. meets the independence standards for directors.

Where can investors find the official press release regarding the board changes at MarineMax?

The press release dated 05-Aug-2025 is included as Exhibit 99.1 to this Form 8-K filing.
Voyager Therapeutics Inc

NASDAQ:VYGR

VYGR Rankings

VYGR Latest News

VYGR Latest SEC Filings

VYGR Stock Data

187.04M
46.03M
16.59%
63.96%
5.65%
Biotechnology
Biological Products, (no Disgnostic Substances)
United States
LEXINGTON